From Analysis:
Trans-synaptic tau spreading and propagation mechanisms in AD
Tau pathology spreads through synaptically connected brain regions in Alzheimer disease following a stereotyped anatomical pattern. Mechanisms of trans-synaptic tau propagation via extracellular vesicles, tunneling nanotubes, and synaptic release need clarification.
This hypothesis proposes that upregulating SULF1/SULF2 sulfatase activity provides dual neuroprotection by simultaneously blocking extracellular tau uptake and preserving intracellular cholinergic function. The molecular mechanism centers on SULF1/SULF2's ability to remove 6-O-sulfate groups from heparan sulfate proteoglycan chains, disrupting the high-affinity binding sites required for pathological tau aggregate uptake by cholinergic neurons. Cholinergic neurons in the nucleus basalis of Meynert and medial septal complex are particularly vulnerable targets due to their extensive axonal projections and high metabolic demands for acetylcholine synthesis.
...No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["SULF1/SULF2
Hypothesis Target"]
B["Rna
Cited Mechanism"]
C["Cellular Response
Stress or Clearance Change"]
D["Neural Circuit Effect
Synapse/Glia Vulnerability"]
E["Neurodegeneration
Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Mechanism: Neuronal activity-dependent tau release occurs via synaptic vesicle fusion, involving SNARE complex assembly (SNAP-25, VAMP2, syntaxin-1) and synaptotagmin-1 calcium sensing. Inhibition of vesicle release would reduce trans-synaptic tau efflux.
Target Gene/Protein/Pathway: SNAP-23, VAMP2, synaptotagmin-1, voltage-gated calcium channels (CaV2.1/CaV2.2)
Supporting Evidence:
Following rigorous critical evaluation, three hypotheses merit substantive feasibility assessment: H3 (HSPG blockade), H6 (TREM2 activation), and H1 (SNARE inhibition). The remaining four hypotheses either possess fatal mechanistic flaws or insufficient evidentiary foundation to justify near-term therapeutic development investment. This assessment covers druggability, biomarkers and model systems, clinical-development constraints, safety considerations, and realistic ti
{
"ranked_hypotheses": [
{
"title": "Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation",
"description": "TREM2 agonism promotes microglial clearance of extracellular tau aggregates. Loss-of-function R47H variant impairs tau clearance and enhances spreading. Agonistic antibodies (AL002) are in clinical development, offering highest feasibility among surviving hypotheses with human genetics support and established regulatory pathway.",
"target_gene": "TREM2",
"dimension_scores": {
"evidence_strength": 0.82,
"novelty": 0.58,
No price history recorded yet
No clinical trials data available
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
neuroscience | 2026-04-04 | archived
No comments yet. Be the first to comment!